nach oben

Erschienen in:

01.12.2014 | News item

Boceprevir, telaprevir: predictive factors for serious morbidity

Erschienen in: Reactions Weekly | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Excerpt

A European review has identified several baseline markers predictive of the development of sepsis, worsening liver function requiring hospitalisation, and death, in patients with liver cirrhosis receiving boceprevir (Victrelis) or telaprevir (Incivo) for the treatment of chronic hepatitis C genotype 1 infection, says the UK MHRA. …

MHRA. Boceprevir (Victrelis) and telaprevir (Incivo): baseline predictive factors for sepsis, worsening liver function, and mortality. Drug Safety Update 8: S1, No. 4, Nov 2014. Available from: URL: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON468289

Titel: Boceprevir, telaprevir: predictive factors for serious morbidity
Publikationsdatum: 01.12.2014
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2014
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-014-5813-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Boceprevir, telaprevir: predictive factors for serious morbidity

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Antivenin-elapidae

Gentamicin

Atomoxetine

DHMA reports of QT prolongation with methadone, (es)citalopram

Vaccines

Lithium